WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010137336) NOVEL α-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/137336 International Application No.: PCT/JP2010/003582
Publication Date: 02.12.2010 International Filing Date: 28.05.2010
IPC:
C07D 239/34 (2006.01) ,A61K 31/505 (2006.01) ,A61K 31/506 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/06 (2006.01) ,A61P 3/10 (2006.01) ,A61P 9/00 (2006.01) ,A61P 9/10 (2006.01) ,A61P 9/12 (2006.01) ,A61P 13/12 (2006.01) ,A61P 25/00 (2006.01) ,A61P 27/02 (2006.01) ,A61P 43/00 (2006.01) ,C07D 239/36 (2006.01) ,C07D 401/04 (2006.01) ,C07D 401/06 (2006.01) ,C07D 401/14 (2006.01) ,C07D 413/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32
One oxygen, sulfur or nitrogen atom
34
One oxygen atom
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
06
Antihyperlipidemics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
12
Antihypertensives
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
12
of the kidneys
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32
One oxygen, sulfur or nitrogen atom
34
One oxygen atom
36
as doubly bound oxygen atom or as unsubstituted hydroxy radical
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
Applicants: MIURA, Toru[JP/JP]; JP (UsOnly)
ONOGI, Kazuhiro[JP/JP]; JP (UsOnly)
TAGASHIRA, Junya[JP/JP]; JP (UsOnly)
WATANABE, Gen[JP/JP]; JP (UsOnly)
SEKIMOTO, Ryohei[JP/JP]; JP (UsOnly)
ISHIDA, Rie[JP/JP]; JP (UsOnly)
AOKI, Hitomi[JP/JP]; JP (UsOnly)
OHGIYA, Tadaaki[JP/JP]; JP (UsOnly)
KOWA COMPANY, LTD.[JP/JP]; 6-29, Nishiki 3-chome, Naka-ku, Nagoya-shi, Aichi 4608625, JP (AllExceptUS)
Inventors: MIURA, Toru; JP
ONOGI, Kazuhiro; JP
TAGASHIRA, Junya; JP
WATANABE, Gen; JP
SEKIMOTO, Ryohei; JP
ISHIDA, Rie; JP
AOKI, Hitomi; JP
OHGIYA, Tadaaki; JP
Agent: SAEKI, Norio; 4th Floor, Aminosan Kaikan Building, 15-8, Nihonbashi 3-chome, Chuo-ku, Tokyo 1030027, JP
Priority Data:
2009-13144329.05.2009JP
Title (EN) NOVEL α-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME
(FR) NOUVEAU DÉRIVÉ D'ACIDE α-PHÉNOXYBENZÈNEACÉTIQUE ET PRÉPARATION PHARMACEUTIQUE LE CONTENANT
(JA) 新規なα-フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
Abstract:
(EN) An α-phenoxybenzeneacetic acid derivative represented by general formula (I), which has both an angiotensin II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, metabolic syndrome or the like, a salt of the derivative, or a solvate of the derivative or the salt; and a pharmaceutical composition containing the derivative, the salt or the solvate. [In the formula, Q represents a group represented by formula (II) or (III) [wherein R1 and R1' independently represent a C1-6 alkyl group; R2 and R2' independently represent a substituted or unsubstituted C1-6 alkyl group; R3 represents a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, or a group represented by formula (IV) [wherein X and Y independently represent CH or N; Z represents a C1-6 alkylene chain, or the like; R11 represents a hydrogen atom, a C6-10 aryl group, or the like; and m represents 0 or 1]; and R4 represents a substituted C1-6 alkyl group]; R5 and R6 independently represent a C1-6 alkyl group: R7 represents a carboxyl group, or the like; R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, or the like; and n represents an integer of 1 to 3.]
(FR) La présente invention concerne un dérivé d'acide α-phénoxybenzèneacétique représenté par la formule générale (I), qui possède à la fois une activité antagoniste du récepteur de l'angiotensine II et une activité d'activation de PPARγ, et qui est utile en tant qu'agent prophylactique et/ou thérapeutique contre l'hypertension, le syndrome métabolique, etc.; un sel de ce dérivé, ou un solvate de ce dérivé ou de ce sel; et une composition pharmaceutique contenant le dérivé, le sel ou le solvate. [Dans la formule, Q représente un groupe représenté par la formule (II) ou (III) [dans laquelle R1 et R1' représentent indépendamment un groupe alkyle en C1-6; R2 et R2' représentent indépendamment un groupe alkyle en C1-6 substitué ou non substitué; R3 représente un atome d'hydrogène, un groupe alkyle en C1-6 substitué ou non substitué, ou un groupe représenté par la formule (IV) [dans laquelle X et Y représentent indépendamment CH ou N; Z représente une chaîne alkylène en C1-6, ou analogue; R11 représente un atome d'hydrogène, un groupe aryle en C6-10, ou analogue; et m représente 0 ou 1]; et R4 représente un groupe alkyle en C1-6 substitué]; R5 et R6 représentent indépendamment un groupe alkyle en C1-6; R7 représente un groupe carboxyle, ou analogue; R8, R9 et R10 représentent indépendamment un atome d'hydrogène, un atome d'halogène, ou analogue; et n représente un entier de 1 à 3].
(JA)  本発明は、アンジオテンシンII 受容体拮抗作用及びPPARγ活性化作用を併せ持ち、高血圧症、メタボリックシンドローム等の予防及び/又は治療剤として有用な、下記一般式(I)で表されるα-フェノキシベンゼン酢酸誘導体若しくはその塩又はそれらの溶媒和物、及びそれを含有する医薬組成物に関する。〔下記式中、Qは、下記(II)又は(III):[式中、R、R1'は、C1-6アルキル基を示し、R、R2'は、置換又は無置換C1-6アルキル基を示し、Rは、水素原子、置換又は無置換C1-6アルキル基、又は下記(IV):[(IV)式中、X、YはCH又はNを示し、ZはC1-6アルキレン鎖等を示し、R11は水素原子、C6-10アリール基等を示し、mは0又は1を示す]を示し;Rは、置換C1-6アルキル基を示す]を示し;R、Rはそれぞれ独立して、C1-6アルキル基を示し、Rは、カルボキシル基等を示し、R、R、R10は、それぞれ独立して、水素原子、ハロゲン原子等を示し;nは1~3の整数を示す〕
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)